S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
S&P 500   5,253.21 (+0.09%)
DOW   39,764.17 (+0.01%)
QQQ   444.19 (-0.14%)
AAPL   171.13 (-1.26%)
MSFT   420.21 (-0.29%)
META   488.37 (-1.11%)
GOOGL   151.27 (+0.27%)
AMZN   180.06 (+0.13%)
TSLA   177.03 (-1.56%)
NVDA   904.68 (+0.24%)
NIO   4.66 (-0.21%)
AMD   180.99 (+0.78%)
BABA   72.19 (+0.84%)
T   17.69 (+0.80%)
F   13.23 (+1.30%)
MU   119.23 (+0.08%)
CGC   9.03 (-5.45%)
GE   176.13 (-2.22%)
DIS   122.15 (+0.97%)
AMC   3.84 (-11.52%)
PFE   27.86 (+0.29%)
PYPL   66.83 (+0.39%)
XOM   115.59 (+0.54%)
NASDAQ:SLN

Silence Therapeutics (SLN) Stock Price, News & Analysis

$22.00
+0.18 (+0.82%)
(As of 09:37 AM ET)
Today's Range
$21.30
$22.09
50-Day Range
$18.41
$26.25
52-Week Range
$4.55
$27.72
Volume
2,541 shs
Average Volume
257,535 shs
Market Capitalization
$658.42 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$57.25

Silence Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
162.4% Upside
$57.25 Price Target
Short Interest
Healthy
0.31% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Silence Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.38) to ($1.36) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.54 out of 5 stars

Medical Sector

485th out of 939 stocks

Pharmaceutical Preparations Industry

227th out of 435 stocks

SLN stock logo

About Silence Therapeutics Stock (NASDAQ:SLN)

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver. The company develops Zerlasiran (SLN360), which is in phase 2 clinical trial for cardiovascular disease associated with elevated lipoprotein(a); and Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trials for the treatment of genetic hematological conditions, including polycythemia vera. It is also developing SLN-COMP-1 and SLN-COMP-2 for complement-mediated diseases; and SLN-HAN-1 and SLN-HAN-2. It has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; Hansoh Pharmaceutical Group Company Limited to develop siRNAs; and Mallinckrodt Pharma IP Trading DAC to develop and commercialize RNAi drug targets designed to silence the complement cascade in complement-mediated disorders. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.

SLN Stock Price History

SLN Stock News Headlines

Your $200 account credit is about to expire
Update to MarketBeat All Access and Save $300 on Your Annual Subscription
7 Biotech Stocks Ready to Ride the Sector's Resurgence
the most reliable asset on earth is making a comeback
Global tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.
Silence Therapeutics earnings: here's what Wall Street expects
Silence Therapeutics PLC (SLN)
See More Headlines
Receive SLN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Silence Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
3/28/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:SLN
Fax
N/A
Employees
109
Year Founded
1999

Price Target and Rating

Average Stock Price Target
$57.25
High Stock Price Target
$75.00
Low Stock Price Target
$42.00
Potential Upside/Downside
+162.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$-53,820,000.00
Net Margins
-171.41%
Pretax Margin
-198.27%

Debt

Sales & Book Value

Annual Sales
$31.55 million
Book Value
$0.71 per share

Miscellaneous

Free Float
29,045,000
Market Cap
$653.07 million
Optionable
Not Optionable
Beta
1.45

Social Links

10 "Recession Proof" Stocks That Will Thrive in Any Market Cover

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

  • Mr. Craig A. Tooman M.B.A. (Age 59)
    President, CEO & Executive Director
    Comp: $1.48M
  • Ms. Rhonda L. Hellums (Age 51)
    CFO & Secretary
    Comp: $900.9k
  • Dr. Steven J. Romano M.D. (Age 65)
    Head of Research & Development
    Comp: $658.03k
  • Dr. Marie Wikstrom Lindholm Ph.D.
    Chief Scientific Officer
  • Ms. Gem Gokmen Hopkins
    Head of IR & Corporate Communications
  • Dr. Barbara A. Ruskin J.D. (Age 64)
    Ph.D., Senior VP and Chief Intellectual Property & Innovation Officer
  • Dr. Eric Floyd M.B.A. (Age 62)
    M.S., Ph.D., Senior Vice President of Regulatory Affairs & Quality Assurance
  • Mr. J.P. Gabriel
    Chief Technical Operations Officer
  • Mr. Curtis Rambaran M.D.
    Chief Medical Officer

SLN Stock Analysis - Frequently Asked Questions

Should I buy or sell Silence Therapeutics stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Silence Therapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SLN shares.
View SLN analyst ratings
or view top-rated stocks.

What is Silence Therapeutics' stock price target for 2024?

4 equities research analysts have issued 12-month price targets for Silence Therapeutics' shares. Their SLN share price targets range from $42.00 to $75.00. On average, they anticipate the company's stock price to reach $57.25 in the next year. This suggests a possible upside of 162.4% from the stock's current price.
View analysts price targets for SLN
or view top-rated stocks among Wall Street analysts.

How have SLN shares performed in 2024?

Silence Therapeutics' stock was trading at $17.37 at the beginning of the year. Since then, SLN shares have increased by 25.6% and is now trading at $21.82.
View the best growth stocks for 2024 here
.

Are investors shorting Silence Therapeutics?

Silence Therapeutics saw a increase in short interest in March. As of March 15th, there was short interest totaling 92,700 shares, an increase of 100.6% from the February 29th total of 46,200 shares. Based on an average trading volume of 241,500 shares, the short-interest ratio is currently 0.4 days.
View Silence Therapeutics' Short Interest
.

When is Silence Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our SLN earnings forecast
.

Who are Silence Therapeutics' major shareholders?

Silence Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include Vivo Capital LLC (1.70%), Parkman Healthcare Partners LLC (0.78%), Cantor Fitzgerald L. P. (0.49%), UBS Group AG (0.23%), Citadel Advisors LLC (0.07%) and SG Americas Securities LLC (0.02%).

How do I buy shares of Silence Therapeutics?

Shares of SLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:SLN) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners